Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: A Spanish nationwide multicenter study

Diagnostic Microbiology and Infectious Disease

Volumn 67, Issue 3, 2010, Pages 251-260

  Cuevas, Oscar ^a   Cercenado, Emilia ^a   Gimeno, Mercedes ^b   Marín, Mercedes ^a   Coronel, Pilar ^b   Bouza, Emilio ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b Tedec Meiji Farma   (Spain)

Author keywords

Cefditoren; Cystitis; Pyelonephritis; Surveillance; Uncomplicated urinary tract infection; Urinary pathogens

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAMASE AMPC; CEFAZOLIN; CEFDITOREN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; NALIDIXIC ACID; NITROFURANTOIN; NORFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; COMPARATIVE STUDY; CONTROLLED STUDY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEMALE; HUMAN; IN VITRO STUDY; INOCULATION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; SPAIN; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AUTOMATION; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SPAIN; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 77953718582     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.02.013     Document Type: Article

References (23)

1. Alós J.I., Garcia-Pena P., Tamayo J. Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections. Rev. Esp. Quimioter. 2007, 20:211-215.
2. Andreu A., Alos J.I., Gobernado M., Marco F., de la Rosa M., Garcia-Rodriguez J.A. Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: a nationwide surveillance study. Enferm. Infecc. Microbiol. Clin. 2005, 23:4-9.
3. Biedenbach D.J., Jones R.N. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Diagn. Microbiol. Infect. Dis. 2009, 64:202-212.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19); approved standard 2009, CLSI, Wayne, PA.
5. Darkes M.J., Plosker G.L. Cefditoren pivoxil. Drugs 2002, 62:319-336. (discussion 337-338).
6. De Cueto M., Lopez L., Hernandez J.R., Morillo C., Pascual A. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob. Agents. Chemother. 2006, 50:368-370.
7. Díaz M.A., Hernández J.R., Martínez-Martínez L., Rodríguez-Baño J., Pascual A. Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido en hospitales españoles: segundo estudio multicéntrico (proyecto GEIH-BLEE 2006). Enferm. Infecc. Microbiol. Clin. 2009, 27:503-510. Grupo de Estudio de Infección Hospitalaria (GEIH).
8. EUCAST European Committee on Antimicrobial Susceptibility Testing (EUCAST): expert rules in antimicrobial susceptibility testing, 2008 Available at:. http://www.srga.org/eucastwt/MICTAB/index.html.
9. Foster R.T., Sr. (2008) Uncomplicated urinary tract infections in women. Obstet Gynecol Clin North Am 35:235-248, viii.
10. Gomáriz M., Vicente D., Pérez-Trallero E. Infecciones urinarias no complicadas. Inf. Ter. Sist. Nac. Salud. 1998, 22:133-141.
11. Granizo J.J., Gimenez M.J., Barberan J., Coronel P., Gimeno M., Aguilar L. Efficacy of cefditoren in the treatment of upper respiratory tract infections: a pooled analysis of six clinical trials. Rev. Esp. Quimioter. 2008, 21:14-21.
12. Griebling T.L. Urologic diseases in America project: trends in resource use for urinary tract infections in women. J. Urol. 2005, 173:1281-1287.
13. Hernandez M., Garcia J., Munoz J. In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin. Rev. Esp. Quimioter. 2009, 22:25-29.
14. Hernandez-Martin J., Roma E., Salavert M., Domenech L., Poveda J.L. Cefditoren pivoxil: a new oral cephalosporin for skin, soft tissue and respiratory tract infections. Rev. Esp. Quimioter. 2006, 19:231-246.
15. Kahan N.R., Chinitz D.P., Waitman D.A., Dushnitzky D., Kahan E., Shapiro M. Empiric treatment of uncomplicated urinary tract infection with fluoroquinolones in older women in Israel: another lost treatment option?. Ann. Pharmacother. 2006, 40:2223-2227.
16. Lerma M., Cebrian L., Gimenez M., Coronel P., Gimeno M., Aguilar L., Garcia de Lomas J. Beta-lactam susceptibility of Escherichia coli isolates from urinary tract infections exhibiting different resistance phenotypes. Rev. Esp. Quimioter. 2008, 21:149-152.
17. Lutters M., Vogt N. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database Syst. Rev. 2002, CD001535.
18. Miller L.G., Tang A.W. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin. Proc. 2004, 79:1048-1053. (quiz 1053-1044).
19. Naber K.G., Schito G., Botto H., Palou J., Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur. Urol. 2008, 54:1164-1175.
20. Sadaba B., Azanza J.R., Quetglas E.G., Campanero M.A., Honorato J., Coronel P., Gimeno M. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study. Rev. Esp. Quimioter. 2007, 20:51-60.
21. Sevillano D., Aguilar L., Alou L., Gimenez M.J., Torrico M., Gonzalez N., Cafini F., Relano M.T., Coronel P., Prieto J. Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil. Antimicrob. Agents Chemother. 2008, 52:1184-1186.
22. Tenover F.C., Emery S.L., Spiegel C.A., Bradford P.A., Eells S., Endimiani A., Bonomo R.A., McGowan J.E. Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and Proteus species can potentially improve reporting of cephalosporin susceptibility testing results. J. Clin. Microbiol. 2009, 47:294-299.
23. Wagenlehner F.M., Weidner W., Naber K.G. An update on uncomplicated urinary tract infections in women. Curr. Opin. Urol. 2009, 19:368-374.